MEDx (Suzhou) Translational Medicine Co., Ltd

Jiangsu,China

home product company profile Certifications Exhibition contact

MEDx (Suzhou) Translational Medicine Co., Ltd

Jiangsu,China

favorite supplier

verified

Ordinary Member

home product company profile Certifications contact

MEDx (Suzhou) Translational Medicine Co., Ltd

favorite supplier

verified

Ordinary Member

MEDx (Suzhou) Translational Medicine Co., Ltd

Jiangsu,China

Scan QR code

Access to mobile station

home product company profile Certifications contact

Compare

Clear All

MMR IHC Panel

FOB Price : Get a Price/Quote

Min.Order : 1 Piece(s)

Certification : CFDA,CE

Brand Name : MEDx

Payment Terms : T/T

contact now Video Conference

favorite

Add to Compare

product information

brand name : MEDx
certification : CFDA,CE
min.order : 1 Piece(s)
warranty : 1 Year
payment terms : T/T
Packaging : /
Specification : 85*75*75mm
place of origin : Jiangsu

product description

MMR IHC Panel Includes the following antibodies:

MLH1 antibody reagent(IHC)
MSH2 antibody reagent(IHC)
MSH6 antibody reagent(IHC)
PMS2 antibody reagent(IHC)

The kits are used for in vitro qualitative testing to assessment the MLH1/ PMS2/MSH6/MSH2 protein expression in 4% neutral (phosphate-buffered) formalin-fixed, paraffin-embedded(FFPE) solid tumor to assist with identifying cancer patients who can be treated with targeted drugs.

Mismatch repair genes are genetic susceptibility genes isolated in hereditary nonpolyposis colorectal cancer(HNPPC), which is mainly including hMLH1, hPMS2, hMHS6, hMSH2, et al.), Mutations in any gene of this system will make the loss of mismatch repair protein expression. All can cause defects in cellular mismatch repair function (mismatch repair deficient, dMMR) and result in genetic instability. It presents with replication errors or Microsatellite instability (Microsatellite instability-high, MSI-H) and is prone to tumors.
Some clinical studies have shown that the PD1/PD-L1 inhibitor Keytruda is highly effective in cancer patients with Mismatch Repair defects (dMMR) or Microsatellite instability (MSI). In May 2017, the US Food and Drug Administration (FDA) approved the PD-1 antibody Keytruda for the treatment of patients which is inoperable or metastatic solid tumors carrying dMMR or high MSI (MSI-H).